{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:27:35Z","timestamp":1792787255252,"version":"4.5.0"},"reference-count":23,"publisher":"BMJ","issue":"10","funder":[{"name":"the Tianjin Key Medical Discipline Construction Project","award":["Grant No. TJYXZDXK-3-004A-2"],"award-info":[{"award-number":["Grant No. TJYXZDXK-3-004A-2"]}]},{"name":"the National Natural Science Foundation of China","award":["Grant No. 82471049"],"award-info":[{"award-number":["Grant No. 82471049"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2026,6,9]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To characterise the clinical and morphological features of ocular surface toxicity induced by human epidermal growth factor receptor 2 (HER2)-targeted antibody\u2013drug conjugates (ADCs) in patients with HER2-positive breast cancer, guiding clinical intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>21 HER2-positive breast cancer patients receiving HER2-ADC therapy were enrolled. Assessments included best corrected visual acuity, the Ocular Surface Disease Index, conjunctival lissamine green staining, tear break-up time, tear meniscus height, Meibomian Gland Score, Strip Meniscometry Tube (SMTube strips), corneal sensitivity (Cochet-Bonnet esthesiometry), anterior segment optical coherence tomography and in vivo confocal microscopy (IVCM) to evaluate morphology, corneal nerve fibre density and length, and endothelial cell density. Transmission electron microscopy (TEM) was performed in selected cases. All parameters were compared from baseline to follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ocular surface toxicity occurred in 85.7% (18\/21) of patients after HER2-ADC therapy, with a mean onset at 28.0\u00b18.4\u2009days. Vortex-like keratopathy progressed from inferior subepithelial microcysts to linear deposits and a vortex pattern. IVCM revealed severe subepithelial nerve fibre fragmentation and loss. TEM revealed epithelial extracellular matrix fibrosis, mitochondrial damage (swelling, disordered cristae, vacuolisation), nuclear alterations (chromatin dispersion, electron-dense deposits) and suspected endocytic vesicles. Lesions appeared dose- and time-dependent and showed partial reversibility. After 12 cycles, corneal structure and transparency showed restoration trends.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HER2-ADC-induced ocular surface toxicity presents as vision loss, dry eye and selective damage to corneal epithelium (vortex-like keratopathy) and nerves (nerve fibre loss and reduced sensitivity), which is dose- and time-dependent and partially reversible.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjo-2026-329526","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:20:20Z","timestamp":1782148820000},"page":"1131-1139","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Microstructural and neural impairment of the ocular surface induced by HER2-targeted ADCs: a prospective longitudinal study with ultrastructural insights"],"prefix":"10.1136","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7880-0559","authenticated-orcid":false,"given":"Liu","family":"Yang","sequence":"first","affiliation":[{"name":"Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengchen","family":"Cui","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulan","family":"Huang","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1087-3249","authenticated-orcid":false,"given":"Fei","family":"Li","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenying","family":"Shang","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaozhen","family":"Zhao","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruibo","family":"Yang","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"2026092202200737000_110.10.1131.1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1156829"},{"key":"2026092202200737000_110.10.1131.2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40487-025-00354-2","article-title":"Practical Guidance on the Clinical Management of Ocular Adverse Events Associated with Belantamab Mafodotin for Patients with Relapsed\/Refractory Multiple Myeloma: Latin American Expert Panel Recommendations","volume":"13","author":"Hungria","year":"2025","journal-title":"Oncol Ther"},{"key":"2026092202200737000_110.10.1131.3","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"2026092202200737000_110.10.1131.4","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/ICO.0000000000002595","article-title":"Clinical and Histological Characterization of Toxic Keratopathy From Depatuxizumab Mafodotin (ABT-414), an Antibody-Drug Conjugate","volume":"40","author":"Lee","year":"2021","journal-title":"Cornea"},{"key":"2026092202200737000_110.10.1131.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32381-3"},{"key":"2026092202200737000_110.10.1131.6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol Ther"},{"key":"2026092202200737000_110.10.1131.7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.adengl.2019.05.021","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE \u2013 Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Edition)"},{"key":"2026092202200737000_110.10.1131.8","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-3202"},{"key":"2026092202200737000_110.10.1131.9","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000868"},{"key":"2026092202200737000_110.10.1131.10","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0064"},{"key":"2026092202200737000_110.10.1131.11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/10781552221139775","article-title":"A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin","volume":"29","author":"Luu","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"2026092202200737000_110.10.1131.12","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_390772","article-title":"Antibody-Drug Conjugates in Gynecologic Cancer","volume":"43","author":"Karpel","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026092202200737000_110.10.1131.13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jamaophthalmol.2025.1008","article-title":"Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma","volume":"143","author":"Lee","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"2026092202200737000_110.10.1131.14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00347-025-02306-7","article-title":"Corneal events with mirvetuximab soravtansine : A review of ocular surface events associated with the tubulin-acting antibody-drug conjugate, mirvetuximab soravtansine","volume":"122","author":"Khoramnia","year":"2025","journal-title":"Ophthalmologie"},{"key":"2026092202200737000_110.10.1131.15","doi-asserted-by":"crossref","first-page":"102117","DOI":"10.1016\/j.ijgc.2025.102117","article-title":"Safety of antibody-drug conjugates in gynecologic cancers: current evidence and management approaches","volume":"35","author":"Ciliberti","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"2026092202200737000_110.10.1131.16","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2045035"},{"key":"2026092202200737000_110.10.1131.17","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10184248","article-title":"The Role of Neuropeptides in Pathogenesis of Dry Dye","volume":"10","author":"Hwang","year":"2021","journal-title":"J Clin Med"},{"key":"2026092202200737000_110.10.1131.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-4835(03)00050-2"},{"key":"2026092202200737000_110.10.1131.19","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41433-021-01612-z","article-title":"The effects of systemic aromatase inhibitors on meibomian glands and corneal structure","volume":"36","author":"A\u011f\u0131n","year":"2022","journal-title":"Eye (Lond)"},{"key":"2026092202200737000_110.10.1131.20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s00347-018-0822-x","article-title":"Clinical picture and diagnosis of neurotrophic keratopathy","volume":"116","author":"Messmer","year":"2019","journal-title":"Ophthalmologe"},{"key":"2026092202200737000_110.10.1131.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.03.004"},{"key":"2026092202200737000_110.10.1131.22","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/OPX.0000000000002042","article-title":"Autologous Serum Eye Drops for Dry Eye: Systematic Review","volume":"100","author":"Quan","year":"2023","journal-title":"Optom Vis Sci"},{"key":"2026092202200737000_110.10.1131.23","doi-asserted-by":"crossref","first-page":"101302","DOI":"10.1016\/j.preteyeres.2024.101302","article-title":"Ocular adverse events associated with antibody-drug conjugates used in cancer: Focus on pathophysiology and management strategies","volume":"103","author":"Gabison","year":"2024","journal-title":"Prog Retin Eye Res"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2026-329526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:21:46Z","timestamp":1790068906000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2026-329526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,22]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/bjo-2026-329526"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2026-329526","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]}}}